| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Cervical Cancer:
GOG 0240: A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BEVACIZUMAB VERSUS THE NON-PLATINUM DOUBLET, TOPOTECAN PLUS PACLITAXEL, WITH AND WITHOUT NCI-SUPPLIED BEVACIZUMAB, IN STAGE IVB, RECURRENT OR PERSISTENT CARCINOMA OF THE CERVIX
(2_20090610_118)
This study is for patients with Stage IV, recurrent or persistent carcinoma of the cervix. Participants will be randomized to one of four arms. Participants will be treated according to the specific arm of the study they are randomized to. Participants will remain on the study cycles until they choose to quit, have disease progression or unacceptable side effects. A cycle will last for 21 days. Participants will need to complete periodic quality of life questionnaires.
- Endomietrial Cancer -
GOG #0210: A MOLECULAR STAGING STUDY OF ENDOMETRIAL CARCINOMA
(1_20070605_118)
All of the patients will be surgically-pathologically staged, consistently evaluated, further treated as needed, and followed for up to 10 years after surgery to document further treatment and outcome. Detailed laboratory testing will be carried out on the thirteen clinical specimens collected and banked for this in-depth research study to learn about the molecular characteristics and biology of endometrial cancer.
- Ovarian, Peritoneal Primary and Fallopian Tube Cancer -
GOG #0213: A PHASE III RANDOMIZED CONTROLLED CLINICAL TRIAL OF OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCER CARBOPLATIN AND PACLITAXEL ALONE OR IN COMBINATION WITH BEVACIZUMAB (NSC #704865, IND #7921) FOLLOWED BY BEVACIZUMAB AND SECONDARY CYTOREDUCTIVE SURGERY IN PLATINUM-SENSITIVE, RECURRENT OVARIAN, PERITONEAL PRIMARY AND FALLOPIAN TUBE CANCER NCI-SUPPLIED AGENTS: BEVACIZUMAB (NSC #704865)
(1_20080203_118)
This is a Phase III randomized controlled clinical trial. This study will look at adding an investigational drug bevacizumab to standard of care for this type of cancer. If participants are surgical candidates, they would be randomized to surgery or no surgery; following surgery they would be randomized to one of two groups. If not a surgical candidate, they would be randomized to one of the two drug treatment groups. One group will receive carboplatin and paclitaxel; and the other group will receive carboplatin, paclitaxel and bevacizumab followed by maintenance bevacizumab. Both groups will receive treatment as long as the participant is benefiting from the treatment with minimal side effects for up to a total of 8 treatments for Group 1 and no limit for Group 2. Participants will be followed by the study doctor for the rest of their lives.
- Risk for Ovarian Cancer -
GOG #0214: PHASE II DOUBLE BLIND RANDOMIZED TRIAL EVALUATING THE BIOLOGIC EFFECT OF LEVONORGESTREL ON THE OVARIAN EPITHELIUM IN WOMEN AT HIGH RISK FOR OVARIAN CANCER
(1_20090209_118)
This is a Phase II Prevention study for women at high risk for an ovarian carcinoma. Participants will receive either the study drug Levonorgestrel or placebo orally once daily. Treatments will last between 4 and 6 weeks; and will end the morning of the participant’s surgery, which will include removal of the tubes and ovaries and is standard of care. Participants will be followed for one year.
- Study Closed to Accrual -
Endometrial Cancer:
GOG 0129Q: A PHASE II EVALUATION OF GEMCITABINE (GEMZAR®, LY 188011) IN THE TREATMENT OF RECURRENT OR PERSISTENT ENDOMETRIAL CARCINOMA (ELI LILLY STUDY B9E-US-X472, NCI version date 11/12/2008 with consent dated 11/12/08)
(2_20090511_118)
Gemcitabine will be the only drug given in this study and will be given at 800mg by intravenous infusion over 30 minutes in two treatments per cycle. The two treatments will be given on day 1 and day 8 of each cycle. A cycle consists of 21 days. Before each cycle, participants will need to have blood work drawn to look at toxicity. With every other cycle, a CT will be done to obtain tumor measurements and/or disease progression or improvement. Participants may remain on the study until disease progression or unacceptable toxicity.
- STUDY CLOSED TO ACCRUAL: Ovaria, Fallopian Tube, Or Primary Peritoneal Cancere - GOG #0126R: A PHASE II EVALUATION OF ABRAXANE® IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER (Abraxis BioScience, Inc. Study #ABX-005)(1_20070902_118)
Use of an investigational drug, Abraxane® given by I.V. infusion over 30 minutes weekly on days 1, 8, and 15 every 28 days until disease progression or adverse effects prohibit further therapy.
- Study Closed to Accrual: Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma - GOG #0170M: A PHASE II EVALUATION OF DASATINIB (SPRYCEL®, NSC#732517) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CARCINOMA
(2_20080712_118)
This is a Phase II open label study in which the study drug Dasatinib will be given to participants to take two tablets in the morning of the initial dose and continue for 28 days (one cycle). If well tolerated, the dose will be increased from 100mg to 140mg per day. Participants may continue on the study for additional cycles until disease progression or withdrawal from the study. Participants will need to keep a medication diary and will be monitored with weekly blood counts; and kidney and liver function blood tests before the start of each cycle.
|
|
